[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myeloid-leukaemia-aml\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myeloid-leukaemia-aml":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,74,98,124,151,174,199,230,259,288],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100576704","phase-2-l-annamycin-for-injection-in-combination-with-cytarabine-injection-as-second-line-therapy-for-remission-induction-in-adult-subjects-with-refractoryrelapsed-aml-100576704",false,"NCT06788756","L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory\u002FRelapsed AML","A Pivotal Phase 2\u002F3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination With Cytarabine Injection Versus Placebo in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory\u002FRelapsed Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Has a pathologically confirmed diagnosis of AML per the 2022 International Consensus Classification (ICC) as adopted in the European LeukemiaNet (ELN) 2022 recommendations for the diagnosis and management of AML. The tests and procedures used to establish the diagnosis of AML should be consistent with the ELN's 2022 recommendations\n2. Has refractory\u002Frelapsed AML after having received only one prior line of therapy\\*.\n\n   \\*A prior line of therapy will be defined as the planned therapy consisting of one or more cycles of episodic treatment or a defined period of continuous treatment. This may consist of single-agent or combination therapy as well as a planned sequence of treatment phases. For example, first-line treatment of AML with induction, consolidation, and alloHSCT is considered one line of therapy. A line of therapy ends when the patient fails to achieve a response within a prespecified period (refractory) or relapses after achieving CR. For the purpose of confirming refractory AML at screening, refractory disease will be defined as CR not being achieved after first line therapy \\[i.e., after 1 cycle of intensive therapy or 180 days after commencing less-intensive therapy (shorter durations of less-intensive therapy may be considered for refractory disease on a case by case basis after discussion between the PI and Medical Monitor)\\].\n3. Between 18 and 80 years of age (inclusive) at the time of signing the informed consent form (ICF).\n4. Has received no chemotherapy, radiation, or major surgery within 2 weeks prior to the first randomized dose of study drug or has recovered from the toxic side effects of that therapy. Hydroxyurea to control white blood cell (WBC) count, supportive measures, and prophylaxes as required under the protocol will be allowed. Treatment of opportunistic or other infections with antibiotics, antifungals, and\u002For antiviral agents, including therapy for meningeal disease (i.e., intrathecal chemotherapy), per institutional standards of care will be allowed during this period, as long as the symptoms of infection have resolved by 1 week prior to the first dose of randomized study drug.\n5. Has received no investigational therapy within 4 weeks prior to the first randomized dose of study drug.\n6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at screening.\n7. Has a life expectancy of greater than six weeks at screening.\n8. Has adequate laboratory results at screening including the following:\n\n   1. Total bilirubin ≤2.0 times the upper limit of normal (ULN). For subjects with leukemic involvement or Gilbert Syndrome, total bilirubin must be ≤3.0 ULN.\n   2. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \\\u003C3.5 times the ULN. For subjects with organ involvement, AST, ALT, and alkaline phosphatase must be ≤4.5 times the ULN.\n   3. Creatinine clearance ≥60 mL\u002Fmin (using Cockcroft-Gault equation).\n9. Can understand and sign the ICF, can communicate with the PI, and can understand and comply with the requirements of the protocol.\n10. For women of childbearing potential (WCBP): Must have a negative serum beta human chorionic gonadotropin (ß-hCG) pregnancy test within 72 hours prior to the first randomized dose of study drug.\n11. For WCBP: Must agree to not donate ova and use a highly effective method of birth control from the time of informed consent through 6 months after their last randomized dose of study drug.\n12. For males with partners who are WCBP: Must agree to not donate sperm and use a highly effective method of birth control from the time of informed consent through 6 months after their last randomized dose of study drug.\n\nExclusion Criteria:\n\n1. Has prior or current diagnosis of acute promyelocytic leukemia (APL) or myelodysplastic syndrome (MDS)\u002FAML\n2. Received prior mediastinal radiotherapy.\n3. Has central nervous system involvement.\n4. Has impaired cardiac function, including any of the following:\n\n   1. Abnormal LVEF at screening \\[per American College of Cardiology, normal LVEF is 50 to 70%\n   2. Valvular heart disease.\n   3. Severe, uncontrolled hypertension.\n   4. Uncontrolled cardiac arrhythmias.\n   5. Recent (≤6 months prior to screening) myocardial infarction.\n   6. Unstable angina.\n   7. Symptomatic congestive heart failure.\n   8. New York Heart Association (NYHA) classification of 3 or 4.\n   9. QT interval\u002Fcorrected QT (QTc) interval \\>480 msec at screening.\n   10. History of additional risk factors for torsade des pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n   11. . Use of concomitant medications with known risk of Torsades de Pointes (TdP) (i.e., drugs that prolong the QT interval and that are clearly associated with a known risk of TdP, even when taken as recommended; refer to Appendix G for examples of such drugs), unless in the clinical judgement of the PI, the medication is imperative and can be used safely with adequate monitoring.\n5. Has clinically relevant serious comorbid medical conditions including, but not limited to, active infection, chronic obstructive or chronic restrictive pulmonary disease, history of positive status for human immunodeficiency virus (virus detected in serum) hepatitis B or hepatitis C with current serious symptoms or signs of underlying chronic infection or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n6. Has evidence of mucositis\u002Fstomatitis at screening or baseline, or has history of severe (≥Grade 3) mucositis\u002Fstomatitis from prior therapy.\n7. Has any condition that, in the opinion of the PI, places the subject at unacceptable risk if he\u002Fshe were to participate in the study.\n8. Has received prior treatment with L-asparaginase.\n9. Pregnant or breastfeeding.\n10. Known hypersensitivity to anthracyclines, cytarabine, the excipients of L Annamycin for Injection or Cytarabine Injection, or contrast media that may be used for the protocol-specified GLS assessments.\n11. Has received a total cumulative prior anthracycline dose of \\> 300 mg\u002Fm2 (daunorubicin equivalent dose).\n12. Has relapsed or refractory AML with a FLT3 mutation, unless resides in a country where gilteritinib is not available.","ALL","18 Years","80 Years",{"count":20,"type":21},312,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This pivotal phase 2\u002F3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory\u002Frelapsed AML is divided into two parts, Part A and Part B.",[28],"Acute Myeloid Leukaemia (AML)","RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2025-03-12",{"date":37,"type":21},"2030-08",{"name":39,"class":40},"Moleculin Biotech, Inc.","INDUSTRY",25,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100604846","a-longitudinal-multi-center-molecular-biomarker-discovery-registry-for-patients-with-hematologic-malignancies-100604846","NCT07154823","A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies","Aquarius","All Cohorts Inclusion Criteria:\n\n1. Willing and able to participate in the research and provide biospecimens\n2. Willing and able to provide informed consent\n\nCohort 001 Inclusion:\n\n1. Have documented diagnosis of AML according to the World Health Organization (WHO) classification\n2. Secondary AML is allowed\n\nCohort 002 Inclusion:\n\n1. Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)\n2. Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)\n3. 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation\n4. 002B (Newly Diagnosed, High Risk): Intended for first line treatment\n5. 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)\n6. 002C (Relapsed \u002F Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment\n7. 002D (Transformed FL): Pathologically confirmed transformation\n\nAll Cohorts Exclusion Criteria:\n\n1\\. Not willing or able to adhere with the study procedures\n\nCohort 001:\n\n1\\. Have received any prior therapy intended for standard of care (SoC) treatment of AML\n\nCohort 002:\n\n1. 002A: Received prior treatment for follicular lymphoma\n2. 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN\n3. 002A: Resected patients with NED\n4. 002B: Intended for active observation\n5. 002B: Received prior treatment for follicular lymphoma","0 Years",{"count":51,"type":21},550,"5 Years","OBSERVATIONAL","The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and\u002For bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.",[28,56],"Follicular Lymphoma ( FL)",[58,59,60,61,62,63],"Hematologic Malignancy","Acute Myeloid Leukemia","AML","Next Generation Sequencing","NGS","Follicular Lymphoma","2026-06-11",{"date":66,"type":33},"2026-06-15",{"date":68,"type":33},"2026-01-27",{"date":70,"type":21},"2035-11",{"name":72,"class":40},"Tempus AI",6,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100640433","phase-2-a-study-to-assess-how-well-the-study-medicine-ipn60340-works-in-combination-with-azacitidine-and-venetoclax-compared-to-placebo-in-combination-with-azacitidine-and-venetoclax-in-participants-with-newly-diagnosed-acute-myeloid-leukemia-who-cannot-receive-intensive-chemotherapy-100640433","NCT07623187","A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy","A Two-part, Phase 2b\u002FPhase 3 Double-blinded, Randomized Study of IPN60340 in Combination With Azacitidine and Venetoclax Versus Placebo in Combination With Azacitidine and Venetoclax in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy.","EVICTION 3","Inclusion Criteria:\n\n1. Participant must be 18 years of age or older, at the time of signing the informed consent.\n2. Have newly diagnosed AML, as per WHO 2022 criteria.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 1 to 2 for participants ≥75 years of age, or 1 to 3 for participants \\\u003C75 years of age\n4. Participants must be considered ineligible for intensive chemotherapy, due to age or comorbidities,\n5. Adequate organ function as indicated in the protocol\n6. Contraceptive use by participant or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.\n7. Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Current diagnosis of:\n\n   I. Acute promyelocytic leukemia (APL) II. Active or uncontrolled central nervous system (CNS) leukemia III. Any γ9δ2TC neoplasm\n2. History of myeloproliferative neoplasms (MPN) including primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia, or MDS\u002FMPN as per WHO 2022 or treatment-related AML\n3. History of other malignancy within the last 2 years.\n4. Rapidly progressing disease in the opinion of the clinical investigator which may preclude treatment in this study.\n5. History of clinically significant or uncontrolled cardiac disorders, within 6 months prior to Cycle 1 Day 1 (C1D1)\n6. White blood cell (WBC) count \\>25 × 10\\^9\u002FL . Cytoreduction can be used before C1D1 and beyond as needed to keep WBC \\\u003C 25 × 10\\^9.\n7. Participants with severe hepatic impairment, e.g., Child-Pugh C, are excluded.\n8. Major surgery within 4 weeks prior to C1D1 or planned during the foreseeable duration of the study.\n9. Any gastrointestinal disorder or malabsorption syndrome that may impair absorption of venetoclax\n10. Uncontrolled or severe bacterial, fungal, viral, and\u002For parasitic infections treated with therapeutic oral or intravenous anti-infective agents. Prophylactic antimicrobials are allowed.\n11. Uncontrolled human immunodeficiency virus (HIV) disease will be excluded. Participants on anti-retroviral therapy should be included as long as their disease is under control, taking precautions to modify their highly active antiretroviral therapy (HAART) regimen to minimize drug interactions.\n12. Presence of hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb) at screening or within 3 months prior to randomization.\n\n    NOTE: Participants with known positive HBsAb may be randomized provided they are hepatitis B-vaccinated and have negative HBsAg and HBcAb.\n13. Positive hepatitis C antibody test result at screening or within 3 months of randomization unless HCV-RNA negative test is documented.\n\n    NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained.\n14. Participant has received strong and\u002For moderate cytochrome P450 (CYP)3A inducers within 7 days prior to the initiation of study treatment.\n15. Participant is unable to swallow capsules or tablets\n16. Prior treatment with hypomethylating agents, chemotherapy, B-cell lymphoma protein (BCL) 2 inhibitors, clinical trial therapy, cellular therapy or allogenic hematopoietic cell transplantation (HCT) for MDS.\n17. Treatment with systemic corticosteroids of \\>10 mg\u002Fday prednisone (or equivalent) or other systemic immunosuppressive medications within 5 half-lives prior to C1D1, or anticipated requirement for systemic immunosuppressive medications during the study.\n18. Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator \\[or medical monitor\\], contraindicates participation in the study.",{"count":83,"type":21},450,[24,25],"The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with acute myeloid leukemia. Acute myeloid leukemia is a rare blood cancer that grows quickly. This study's main aim is to compare the percentage of participants who reach complete remission within the first 6 months of treatment between the 2 study arms (study drug and standard medicines compared to placebo and standard medicines).\n\nIn this study all participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. Venetoclax will be given as a tablet by mouth once each day in 28-day cycles. Azacitidine will be given by injection under the skin (subcutaneously) or through the veins (intravenously) daily for the first 7 days of each 28-day cycle. IPN60340 or placebo (depending on which arm of the study the participant is assigned to) will be given through the veins (intravenously) on day 1 of each 28-day cycle.\n\nThere will be 4 periods in this study:\n\n* A screening period (up to 28 days) to assess whether the participant can take part requiring at least 1 visit to the study center.\n* A treatment period where all eligible participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. The study requires 8 visits for the first month followed by 1 visit every month until unacceptable toxicity, disease progression, the start of new cancer treatment, or study closure, whichever is first.\n* A safety follow-up period (at 28 days (±3 days) after the last dose of study medicine) to assess safety after participants have finished treatment.\n* A long-term follow-up period where participants' health will be monitored using a telephone call or clinic visit every 12 weeks until the end of study.\n\nParticipants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), bone marrow aspirates (sampling of the liquid part of the bone marrow). Some participants will also undergo pregnancy testing. Participants in the Phase 3 portion of the study will also be asked to fill in questionnaires.\n\nThe time each participant will be in this study will vary based on how well the medicine works to treat the participant's AML. Azacitidine and venetoclax plus either IPN60340 or placebo will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.",[28,87],"Acute Myeloid Leukaemia","NOT_YET_RECRUITING","2026-05-29",{"date":91,"type":33},"2026-06-03",{"date":93,"type":21},"2026-11-01",{"date":95,"type":21},"2032-05-31",{"name":97,"class":40},"Ipsen",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":123},"100597554","phase-2-efficacy-of-hypomethylating-agents-vs-intensive-chemotherapy-in-acute-myeloid-leukemia-using-5hmc-as-a-blood-based-minimal-residual-disease-marker-100597554","NCT07060001","Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","Evaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. The patient (or legally acceptable representative if applicable) provides written informed consent for the trial. Spanish speaking patients will be included and translation services will be provided as needed.\n2. Male or female, 18 years of age or older, on the day of informed consent signing.\n3. Newly diagnosed de novo AML\n\n5\\. Expected life expectancy of at least 6 months 6. Willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits and examinations. 7. Women with childbearing potential and men should practice at least one of the following methods of birth control throughout the study and for 6 for women and 3 months for men after the last dose of study therapy:\n\n1. Total abstinence from sexual intercourse (periodic abstinence not acceptable);\n2. Surgically sterile partner(s) including vasectomy, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy;\n3. Practicing 2 effective methods of contraception (at least 1 highly effective, method of contraception \\[See Appendix 4\\]). WOCBP should only be included after a confirmed negative serum pregnancy test.\n\nExclusion Criteria:\n\n1. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of trial treatment administration.\n2. The patient has serious and\u002For uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study\n3. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n4. Confirmed positive pregnancy test in WOCBP.",{"count":106,"type":21},112,[24],"This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease (MRD) in patients with newly diagnosed acute myeloid leukemia (AML). The study compares the efficacy of hypomethylating agent (HMA)-based therapy versus intensive induction chemotherapy, using the 5hmC biomarker to guide post-induction treatment decisions. Approximately 112 adult patients will be enrolled and assigned to treatment arms based on a stratified sampling scheme. Blood samples will be collected at defined intervals to assess MRD status. Primary endpoints include minimal residual disease (MRD) negativity rate, duration of remission, event-free survival (EFS), and overall survival (OS).",[110,28],"Acute Myeloid Leukemia (AML)",[60,112,59],"Leukemia","2026-03-05",{"date":115,"type":33},"2026-03-06",{"date":117,"type":21},"2026-04",{"date":119,"type":21},"2029-12",{"name":121,"class":122},"The Methodist Hospital Research Institute","OTHER",1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100604335","phase-1-a-multi-site-break-through-cancer-trial-targeting-measurable-residual-disease-in-patients-with-acute-myeloid-leukemia-a-phase-12-study-of-tagraxofusp-azacitidine-and-venetoclax-100604335","NCT07148180","A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1\u002F2 Study of Tagraxofusp, Azacitidine, and Venetoclax","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* History of known diagnosis of Acute Myeloid Leukemia (including de novo, secondary or AML arising from MDS).\n* Subjects must be in CR, CRi, or CRh with \\\u003C5% morphologic blasts in bone marrow\n* Any evidence of CD123+ by central assessment.\n* Participants must have measurable disease, defined as ≥ 0.1% by multiparametric flow cytometric assay as assessed by central laboratory\n* ECOG performance status ≤2 (see Appendix A).\n* Subjects must have adequate organ and marrow function as defined below:\n\n  * total bilirubin ≤ 1.5 x institutional upper limit of normal unless due to Gilbert or non-hepatic in origin\n  * AST(SGOT) and ALT(SGPT) ≤ 3.0 × institutional upper limit of normal\n  * Creatinine clearance ≥ 45 ml\u002Fmin GFR by MDRD\n* Albumin ≥ 3.2 g\u002FdL\n* Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA or echocardiogram within 30 days of first protocol treatment. This can be locally assessed.\n* Pregnancy potential: Female subjects of childbearing potential must have negative results for pregnancy test. Females with reproductive potential are advised to use effective contraception during study treatment and for at least 6 months after last dose. Similarly, males with female partners of reproductive potential are advised to use effective contraception during treatment and for at least 3 months after the last dose. Men must agree to abstain from donating sperm.\n* Subject is able and willing to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n* Prior treatment with CD123-targeted therapy\n* Known diagnosis of acute promyelocytic leukemia.\n* Subjects who received intensive anti-leukemic chemotherapy within 2 weeks from first dose of study. If on venetoclax, subjects must be off venetoclax for at least 5 days\n* Subjects pre-arranged for SCT are only excluded if it is imminent.\n* History of prior allogeneic stem cell transplant\n* Subject has uncontrolled, clinically significant pulmonary disease (e.g. COPD, pulmonary hypertension, etc.) that in the opinion of the Investigator would put the subject at significant risk for pulmonary complications during the study.\n* Subject has experienced Grade 3 or Grade 4 capillary leak syndrome (CLS) in the past for any reason\n* Subjects with known HBV and\u002For HCV infection must have undetectable viral load during screening (HBV and HCV testing are not required.) Participants with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.\n* Subjects with known HIV positivity are permitted provided they have undetectable viral load at the time of screening (HIV testing is not required).\n* Subject has a concurrent malignancy or prior malignancy within the 6-month period before screening. To be eligible, subjects must be in remission from the prior malignancy at least 6 months prior to screening and all treatment-related toxicities must have resolved to ≤ Grade 1 except for alopecia. Exceptions include adequately treated basal or squamous cell skin cancer, superficial bladder cancer, adequately treated carcinoma in situ of the cervix or uterus, or carcinoma in situ of the breast, previous malignancy confined and surgically resected (or successfully treated with other modalities) with curative intent, which are permissible for inclusion. Maintenance therapy, hormonal therapy, or steroid therapy for a well-controlled concurrent malignancy is allowed.\n* Subject has uncontrolled systemic fungal, bacterial, or viral infection, defined as ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics, antivirals, or antifungals, either IV or oral. However, subjects with controlled infection still requiring anti-infectives are eligible.\n* Subjects with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, that have New York Heart Association Functional Class III or IV symptoms.\n* Subject has evidence of ongoing alcohol or drug abuse\n* Subjects with known active\u002Fsymptomatic CNS involvement. CNS prophylaxis allowed\n* Subjects receiving moderate or strong P450 3A (CYP3A) inducers within 7 days of start of study therapy. See Appendix B for examples\n* Subjects with uncontrolled intercurrent illness.\n* Administration or consumption of any of the following within 3 days prior to the first dose of study drug:\n\n  * grapefruit or grapefruit products\n  * Seville oranges (including marmalade containing Seville oranges)\n  * star fruit\n* Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with trial therapy, breastfeeding should be discontinued if the mother is treated on trial.",{"count":131,"type":21},31,[133,24],"PHASE1","The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence.\n\nThe names of the study drugs involved in this study are:\n\n* Tagraxofusp (a type of CD123-directed cytotoxin)\n* Azacitidine (a type of standard of care cytidine nucleoside analog)\n* Venetoclax (a type of standard of care BCL-2 inhibitor)",[28,112,136,137],"Blood Cancer","Blood Cancers",[59,60,139,140,136,137],"Measurable Residual Disease","Myeloid Neoplasms","2026-02-03",{"date":143,"type":33},"2026-02-05",{"date":145,"type":33},"2026-02-02",{"date":147,"type":21},"2030-12-31",{"name":149,"class":122},"Jacqueline Garcia, MD",2,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100613240","phase-2-sorafenib-combined-with-venetoclax-as-pre-emptive-therapy-strategy-for-mrd-aml-a-prospective-single-arm-multicenter-clinical-study-100613240","NCT07264010","Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for Measurable Residual Disease Persisting Acute Myeloid Leukemia: a Prospective, Single-arm, Multicenter Clinical Study","Inclusion Criteria:\n\n* Voluntary signing of informed consent form;\n* Liver and kidney function: Blood bilirubin ≤ 35 μ mol\u002FL, AST\u002FALT \\\u003C 2 times the upper limit of normal, blood creatinine ≤ 150 μ mol\u002FL;\n* Normal heart function (EF ≥ 50%, NYHA I\u002FII);\n* Physical condition score 0-2 (ECOG score);\n* Non pregnant and lactating women. For all women of childbearing age, a pregnancy test must be conducted to determine hCG levels in order to exclude pregnancy status;\n* For all men of childbearing age, contraceptive measures must be taken during sorafenib treatment until 3 months after discontinuation.\n\nExclusion Criteria:\n\n* Acute promyelocytic leukemia;\n* Hematological non-remisssion or recurrence;\n* Uncontrolled infection or grade 3-4 graft-versus-host disease (GVHD);\n* Allergies or contraindications to any of the drugs involved in the protocol;\n* Severe organ dysfunction such as heart, liver, kidneys, lungs, etc.","65 Years",{"count":160,"type":21},87,[24,25],"The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.",[28,164],"Measurable Residual Disease (MRD)","2025-11-23",{"date":167,"type":33},"2025-12-04",{"date":169,"type":21},"2025-12-01",{"date":171,"type":21},"2028-12-30",{"name":173,"class":122},"Nanfang Hospital, Southern Medical University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":150},"100611729","maintenance-venetoclax-in-aml-fit-patients-100611729","NCT07244367","Maintenance Venetoclax in AML Fit Patients","Maintenance Venetoclax Based Therapy Post Complete Remission in AML Fit Patients","Inclusion Criteria:\n\n* Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory \u002F recurrant AML patients who attained CR after 2nd line .\n\nExclusion Criteria:\n\n* Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation","60 Years",{"count":183,"type":21},80,[185],"NA","this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.",[28],[60,189],"Venetoclax","2025-11-17",{"date":192,"type":33},"2025-11-24",{"date":194,"type":33},"2025-09-01",{"date":196,"type":21},"2027-09-01",{"name":198,"class":122},"Sohag University",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":150},"100591948","phase-2-rvu120-rollover-study-100591948","NCT06987058","RVU120 Rollover Study","An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study","ROVER-01","Inclusion Criteria:\n\n1. The participant is enrolled in a RVU120 clinical study and receiving RVU120-based treatment given alone or in combination for at least 5 cycles.\n2. The participant is currently benefiting from, and expected to continue to benefit from, RVU120-based treatment according to the criteria set out in the parent study protocol and according to the judgment of the investigator and sponsor.\n3. The participant does not have access to commercially available comparator anticancer therapy.\n4. Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n5. The participant signed the rollover study ICF prior to any study-related procedure or study data collection.\n6. The participant agrees not to donate blood during study participation and until 28 weeks (\\~6.5 months) after the last dose.\n7. The investigator considers the participant to be eligible for participation in the rollover study.\n\nExclusion Criteria:\n\n1. Presence of toxicity that cannot be adequately managed.\n2. Concurrent participation in any therapeutic clinical study other than the parent study.",{"count":208,"type":21},10,[24],"This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study.\n\nTo be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.",[212,28,213],"Advanced Solid Tumors","High-risk Myelodysplastic Syndrome",[215,216,217,218,219,60,220],"Relapse","Refractory","Metastatic","Advanced","Solid Tumor","Myelodysplastic syndrome","2025-09-23",{"date":223,"type":33},"2025-09-24",{"date":225,"type":21},"2025-12-15",{"date":227,"type":21},"2026-08",{"name":229,"class":40},"Ryvu Therapeutics SA",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":123},"100597727","feasibility-and-safety-of-home-blood-count-measurement-and-transfusions-in-patients-with-acute-myeloid-leukemia-100597727","NCT07062250","Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia","Feasibility and Safety of Home Blood Count Measurement and Transfusions by Systematically Educated Patients With Acute Myeloid Leukemia","HOME-BLOOD","Inclusion Criteria:\n\n* ≥ 18 years old\n* newly diagnosed with AML within four weeks\n* scheduled to receive home-based chemotherapy.\n\nExclusion Criteria:\n\n* Patients who do not understand or speak Danish\n* Incapable of performing home-based CBC measurements and administration of transfusions.\n* Patients will be discontinued if they do not achieve remission after the second chemotherapy cycle.",{"count":239,"type":21},15,[185],"The aim is to investigate the feasibility, safety, and complication rates of patient's self-measurement of CBC and self-administration of blood and platelet transfusions at home and examine the performance of patients conducting at-home monitoring of their blood pressure, pulse rate, saturation, and temperature before and after transfusion. Furthermore, to evaluate the health economic consequences of our innovative approach, specifically, the anticipated reduction in reliance on nurse-driven services.\n\nThis study is a single-arm feasibility study with patients newly diagnosed with Acute Myeloid Leukemia. The study will be conducted at the Department of Hematology, Rigshospitalet.\n\nPatients are included if they are ≥ 18 years old, newly diagnosed with AML within four weeks, and scheduled to receive home-based chemotherapy. Patients are excluded if they do not speak Danish or are not assessed to be capable of performing home-based CBC measurements and administration of transfusions. Patients will be discontinued if they do not achieve remission after the second chemotherapy cycle.\n\nIncluded patients will receive comprehensive training and certification to perform CBC measurements, self-administer transfusions, and monitor selected vital parameters including blood pressure, pulse rate, oxygen saturation, and temperature.\n\nIt is hypothesized that the study can demonstrate the logistic, technical, and economic feasibility and safety of educating patients with AML undergoing intensive chemotherapy, to independently conduct self-measurement of complete blood count (CBC), self-administration of transfusions at home, and examine the performance of patients conducting at-home monitoring of their blood pressure, pulse rate, saturation, and temperature before and after transfusion.",[28],[244,245,246,247,248,249],"Home transfusion","Hematology","Blood transfusion","Home based treatment","Acute leukemia","Patient empowerment","2025-07-02",{"date":252,"type":33},"2025-07-14",{"date":254,"type":33},"2024-04-01",{"date":256,"type":21},"2026-03",{"name":258,"class":122},"Rigshospitalet, Denmark",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":275,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":123},"100581075","safely-delivered-targeted-high-dose-irradiation-followed-by-adoptive-immunotherapy-with-regulatory-and-conventional-t-cells-to-increase-potency-of-hematopoietic-stem-cell-transplantation-in-high-risk-acute-leukemia-100581075","NCT06845592","Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia","SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia","SHARP","Inclusion Criteria:\n\n* AML patients\n\n  * Diagnosis of AML with indication to allogeneic hematopoietic cell transplantation.\n  * Diagnosis of adverse genetic risk leukemia or presence of MRD or active disease (bone marrow infiltration 5-30%) at the time of the transplant procedure.\n  * Availability of a hematopoietic stem cell donor (family or unrelated HLA-matched or HLA-haploidentical with the patient) suitable to be treated with G-CSF (10 mcg\u002Fkg\u002Fdie) for a maximum of 7 days and able to tolerate 2 or more leukaphereses.\n  * Age ≥ 18 and ≤ 65 years\n  * ECOG ≤ 2\n  * HCT-CI ≤ 4 (51,52)\n  * Absence of relevant psychiatric diseases\n  * Signature of the informed consent\n\nALL patients\n\n* Diagnosis of ALL, either T or B (Philadelphia negative) or mixed phenotype with indication to allogeneic transplant\n* Presence of MRD or active disease (bone marrow infiltration 5-30%) or patient with ≥ 2nd complete hematologic remission at the time of the transplant procedure.\n* Availability of a hematopoietic stem cell family donor (family or unrelated HLA-matched or HLA-haploidentical with the patient) suitable to be treated with G-CSF (10 mcg\u002Fkg\u002Fdie) for a maximum of 7 days and able to tolerate 2 or more leukaphereses.\n* Age ≥ 18 and ≤ 65 years\n* ECOG ≤ 2\n* HCT-CI ≤ 4\n* Absence of relevant psychiatric diseases\n* Signature of the informed consent\n\nExclusion Criteria:\n\n* AML patients\n\n  * AML in CR MRD-\n  * AML with \\> 5% peripheral blasts or bone marrow infiltration ≥ 30%\n  * Age \\\u003C 18 years or \\> 65 years\n  * ECOG \\> 2\n  * Unacceptable lung, liver, kidney, and\u002For heart function and presence of relevant psychiatric diseases according to clinical judgment\n  * Pregnancy\n  * No signature of the informed consent\n* ALL patients\n\n  * ALL with \\> 5% peripheral blasts or bone marrow infiltration ≥30%\n  * Philadelphia positive ALL\n  * Age \\\u003C 18 years or \\> 65 years\n  * ECOG \\> 2\n  * Unacceptable lung, liver, kidney, and\u002For heart function and presence of relevant psychiatric diseases according to clinical judgment\n  * Pregnancy\n  * No signature of the informed consent",{"count":268,"type":21},51,[185],"The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg\u002FTcon adoptive immunotherapy for high-risk acute leukemia patients.",[28,272,273,274],"Acute Lymphoblastic Leukemia ALL","High Risk Leukaemia","Leukaemia Relapse",[60,16,265,276,277,278,215],"Total marrow\u002Flymphoid irradiation","Treg","Tcon","2025-03-01",{"date":281,"type":33},"2025-03-04",{"date":283,"type":33},"2025-02-25",{"date":285,"type":21},"2031-01",{"name":287,"class":122},"University Of Perugia",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":123},"100576298","phase-2-nk-cell-infusion-for-remission-consolidation-in-aml-a-phase-ii-trial-100576298","NCT06783478","NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial","Phase II Multicenter, Double-Blind, Prospective, Randomized Clinical Trial of NK Cell Infusion for Remission Consolidation in Patients With Acute Myeloid Leukemia","NKLMA","Inclusion Criteria:\n\n* Male or female patients aged 18 to 59 years, and 60 to 75 years if their score is \\\u003C 0.4 on the 10-minute Comprehensive Geriatric Assessment (CGA-10);\n* Recently diagnosed acute myeloid leukemia, excluding acute promyelocytic leukemia confirmed by the molecular finding of PML-RARA or the presence of t(15:17) in genetic evaluation;\n* In first complete hematologic remission after remission induction;\n* Eligible, in the opinion of the principal investigator, to undergo consolidation chemotherapy with HDAra-C;\n* No history of NYHA \\> III heart failure, acute myocardial infarction, or unstable angina in the past 6 months;\n* Negative beta-HCG test for women of childbearing potential and agreement to use contraceptive methods throughout the treatment, from the time of informed consent signature until one month after the last dose of treatment;\n* Non-reactive HIV serology;\n* No prior investigational therapy in the 4 weeks before study enrollment;\n* Availability of a haploidentical peripheral blood donor;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Patients under 18 years of age; or aged 60 to 75 years with a score \\> 0.4 on the CGA-10 scale; or over 76 years of age, regardless of the score on the CGA-10 scale.\n* Diagnosis of acute promyelocytic leukemia confirmed by the molecular finding of PML-RARA or the presence of t(15:17) in genetic evaluation.\n* Failure to achieve first complete hematologic remission after remission induction.\n* Ineligible, in the investigator's opinion, to undergo consolidation chemotherapy with HDAra-C.\n* History of NYHA \\> III heart failure, acute myocardial infarction, or unstable angina in the past 6 months.\n* Positive beta-HCG test for women of childbearing potential or non-compliance with using contraceptive methods throughout the treatment, from the time of informed consent signature until one month after the last dose of treatment.\n* Reactive HIV serology.\n* Prior investigational therapy in the four weeks preceding study enrollment.\n* Lack of availability of a haploidentical peripheral blood donor.\n* Failure to sign the informed consent form.","75 Years",{"count":298,"type":21},98,[24],"Acute Myeloid Leukemia (AML) is a complex and rapidly progressive disease with high mortality. Although significant progress has been made in recent years with the development of new drugs, resulting in better therapeutic tolerability and increased survival, disease relapse occurs in most cases. Adoptive immunotherapy has been increasingly emerging as an innovative alternative for cancer treatment. Among the immune cells tested, natural killer (NK) cells appear to exert significant antileukemic activity, particularly against AML, as demonstrated by numerous phase I\u002FII studies published in the literature, including studies from our group.\n\nThis study aims to test whether haploidentical NK cells from healthy individuals, expanded and activated in vitro, administered when the disease is nearly eradicated by chemotherapy, can eliminate residual disease, delaying or eliminating the possibility of relapse. It is a randomized, superiority, double-blind, placebo-controlled clinical trial conducted at two treatment centers in Brazil. Adult patients aged 18 to 75 years with AML, from any risk group, in complete remission after completing standard treatment, will be included. Those with a bone marrow donor and eligible for this treatment will be allowed to undergo hematopoietic stem cell transplantation (HSCT). The study's objective is to determine whether the infusion of haploidentical NK cells immediately after high-dose chemotherapy results in increased event-free survival (EFS), overall survival (OS), and lower minimal residual disease (MRD) during follow-up or immediately before HSCT compared to patients undergoing the same treatment without NK cell infusion. A total of 98 participants in complete remission (CR) will be randomized to receive 6 infusions of 1 x 10⁷ NK cells\u002Fkg or 6 placebo infusions.\n\nAll participants will be evaluated for immune recovery at the cellular and molecular levels, and their immune profiles will be compared to analyze cellular response mechanisms.",[28],[303,304,59],"Adoptive Immunotherapy","Natural Killer Cells","2025-01-14",{"date":307,"type":33},"2025-01-20",{"date":309,"type":21},"2025-04-01",{"date":311,"type":21},"2027-12-31",{"name":313,"class":122},"Hospital de Clinicas de Porto Alegre"]